Stay updated with breaking news from Ribose Polymerase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differ
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differentiated PARP inhibitor RP12146, indicates
Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labeled "Variant of Concern 202012/01" by Public Health England (PHE), an agency o...
E-Mail Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labelled "Variant of Concern 202012/01" by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on Decembe...
(2) Press Release Hørsholm, Denmark (26 January 2021) - Allarity Therapeutics A/S ("Allarity" or the "Company") today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU). The virus variant was labelled "Variant of Concern 202012/01" by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to ...